F
Francesco M. Marincola
Researcher at National Institutes of Health
Publications - 473
Citations - 41473
Francesco M. Marincola is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Immune system & Antigen. The author has an hindex of 94, co-authored 462 publications receiving 38129 citations. Previous affiliations of Francesco M. Marincola include Society for Immunotherapy of Cancer & Virginia Commonwealth University.
Papers
More filters
Journal ArticleDOI
Targeting vaccinia to solid tumors with local hyperthermia.
Eugene Chang,Sricharan Chalikonda,Josef Friedl,Hui Xu,Giao Q. Phan,Francesco M. Marincola,H. Richard Alexander,David L. Bartlett +7 more
TL;DR: In vivo and in vitro experiments, regional hyperthermia improves vaccinia targeting to tumors, and thereby enhances the antitumor response.
Journal ArticleDOI
Functional characterization of CTL against gp100 altered peptide ligands.
TL;DR: Two major and one minor CTL recognition pattern were observed, suggesting that multiple, rationally designed modified tumor peptides for the same epitope stimulate a broad CTL response by activating multiple CTL capable of cross-reacting with the natural antigenic peptide.
Journal ArticleDOI
Identification of a Mutated Fibronectin As a Tumor Antigen Recognized by CD4+T Cells Its Role in Extracellular Matrix Formation and Tumor Metastasis
TL;DR: It is shown that a mutated fibronectin (FN) gene contains a mutation that results in the substitution of lysine for glutamic acid and gives rise to a new T cell epitope recognized by CD4+ T cells, which indicates the importance of CD4- T cells in controlling the spread of tumor cells to distant anatomic sites.
Journal ArticleDOI
The transcription factor BACH2 promotes tumor immunosuppression
Rahul Roychoudhuri,Rahul Roychoudhuri,Robert L. Eil,David Clever,Christopher A. Klebanoff,Madhusudhanan Sukumar,Francis M. Grant,Zhiya Yu,Gautam U. Mehta,Hui Liu,Ping Jin,Yun Ji,Douglas C. Palmer,Jenny H. Pan,Anna Chichura,Joseph G. Crompton,Shashank J. Patel,David F. Stroncek,Ena Wang,Francesco M. Marincola,Klaus Okkenhaug,Luca Gattinoni,Nicholas P. Restifo +22 more
TL;DR: Mechanistically, BACH2 promoted tumor immunosuppression through Treg-mediated inhibition of intratumoral CD8+ T cells and IFN-γ, and was identified as a key component of the molecular program of tumor immunOSuppression and identify therapeutic targets for the reversal of immunosppression in cancer.